SMC publishes a Collaborative Advice Document for tixagevimab-cilgavimab (Evusheld®) for prevention of COVID-19

SMC has collaborated with the National Institute for Health and Care Excellence (NICE) on Technology Appraisal (TA), TA900: tixagevimab-cilgavimab for preventing COVID-19.

SMC has now published a Collaborative Advice Document and recommendations are aligned with the NICE guidance.

Tixagevimab-cilgavimab (Evusheld®) is not recommended for use in NHSScotland for preventing COVID-19.

You can find the NICE final guidance here: Overview | Tixagevimab plus cilgavimab for preventing COVID-19 | Guidance | NICE